drugset / Trial / NCT00982878

The Maraviroc Central Nervous System (CNS) Study

NCT00982878

Phase 1 Completed 13 enrolled Imperial College London Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Timeline

Start
2009-09
Primary completion
2010-07
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg